Oral booster probiotic bifidobacteria in SARS-COV-2 patients
| Autor: | Huseyin Sancar Bozkurt, Ömer Bilen |
|---|---|
| Přispěvatelé: | Bilen, Ömer |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Turkey Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology bifidobacteria Severity of Illness Index law.invention Probiotic law Internal medicine medicine Immunology and Allergy Effective treatment Humans Immunologic Factors University medical Original Research Article Mortality Bifidobacterium Retrospective Studies Pharmacology Probiotic therapy biology business.industry SARS-CoV-2 Interleukin-6 Mortality rate Probiotics COVID-19 Length of Stay Middle Aged biology.organism_classification COVID-19 Drug Treatment Hospitalization Treatment Outcome Female business probiotic |
| Zdroj: | International Journal of Immunopathology and Pharmacology |
| ISSN: | 2058-7384 0394-6320 |
| Popis: | Oral booster-single strain probiotic bifidobacteria could be a potential strategy for SARS-CoV-2. This study aims to evaluate the role of oral probiotic Bifidobacterium on moderate/severe SARS-CoV-2 inpatients. In this single-center study, we analyzed data of 44 moderate/severe inpatients with diagnosed COVID-19 in Istanbul Maltepe University Medical Faculty Hospital, 2020 from 1 November 2020 to 15 December 2020. Clinical and medication features were compared and analyzed between patients with or without probiotic. In result, 19 of the 44 patients (43.18%) who were administrated with oral booster-single strain probiotic were discharged with the median inpatient day of 7.6 days which were significantly shorter than those of patients without probiotic. There were significant differences in inpatient days, radiological improvement at day 6 and week 3, and reduction in interleukin-6 levels in those receiving oral probiotic therapy. Although the mortality rate was 5% in the probiotic group, it was 25% in the non-probiotic group. Booster-single strain probiotic bifidobacteria could be an effective treatment strategy for moderate/severe SARS-CoV-2 inpatients to reduce the mortality and length of stay in hospital. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|